Salute e Benessere

Hisense Wins Red Dot Award 2024 and iF Design Award 2024 for the ERF6A66 Solar…

The Hisense ERF6A66 Remote Control is compatible with Hisense UX, U7 and U8 TVs in the European and Oceanian markets and adopts a sleek and geometric design elevated by its concise shape and ergonomic hand-feeling. Created to complement any home lifestyle, the solar charging panel is strategically positioned on the top surface, aligning with user placement habits and optimizing solar area efficiency. The seamless integration of the solar area and the remote's control main body not only enhances…
PR Newswire
23/05/2024

THE LEGO GROUP CELEBRATES CHILDREN'S UNIQUE CURIOSITY ABOUT THE COSMOS BY ASKING…

A new global study1 by the LEGO Group finds that 86 percent of kids aged four to 14 are interested in finding new planets, stars and galaxies, and 77 percent want to travel to space. Additionally, more than 3 in 5 (68 percent) children believe there are aliens in space, and 64 percent say they would want to meet one. A new global study 1by the LEGO Group finds that 86 percent of kids aged four to 14 are interested in finding new planets, stars and galaxies, and 77 percent want to travel to…
PR Newswire
23/05/2024

Degenerative Disc Disease Treatment Market to Reach $46.2 Billion Globally by…

Request Sample of the Report on Degenerative Disc Disease Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/A269439 Request Sample of the Report on Degenerative Disc Disease Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/A269439 Prime Determinants of Growth The increasing prevalence of degenerative disc disease (DDD) among the aging population, growing awareness about spine health and available treatment options, and the...
PR Newswire
23/05/2024

MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick…

The benefits of the SCOPEYE 3D Micro Surgery Solution are manifold. With high-resolution 3D optics, surgeons gain unparalleled visual clarity and depth perception, enhancing their precision and accuracy during procedures. Additionally, the solution offers significant cost efficiencies, maximised ergonomic comfort, and advanced features such as 3D recording and training capabilities, further enhancing patient care and surgical outcomes. The benefits of the SCOPEYE 3D Micro Surgery Solution are…
PR Newswire
23/05/2024

LiuGong Makes Its Debut at CSPI-EXPO 2024

On the first day of the exhibition, LiuGong held the Electric Product launch at its booth. Industry media from Japan and Xinhua News Agency conducted an exclusive interview with Zeng Guang'an, Chairman and CEO of LiuGong. "Since embarking on the development of electric technology in 2014, LiuGong has made significant achievements in the field of electric intelligence over a decade of relentless pursuit and innovation. LiuGong's electric equipment has been successfully promoted in China…
PR Newswire
23/05/2024

Disclosure of voting rights for Chair of the Board

Hans Peter Bøhn is chair of PCI Biotech's board of directors and shall open the annual general meeting of the Company on 24 May 2024. Mr. Bøhn holds 123,662 shares, representing 0.3 percent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 4,288,185 additional shares. In total, Mr. Bøhn will represent and vote for 11.8 percent of the share capital. A major part of the powers of attorney are without voting instructions. The powers of...
Nasdaq GlobeNewswire
23/05/2024

ANNEMARIE BÖRLIND Leads the Way in China's Cosmetic Paradigm Shift with Vegan…

ANNEMARIE BÖRLIND is now seizing the opportunity to unveil a groundbreaking skincare line tailored to the demands of the modern, conscious consumer. ANNEMARIE BÖRLIND is now seizing the opportunity to unveil a groundbreaking skincare line tailored to the demands of the modern, conscious consumer. NatuCollagen is a pioneering skincare series that leverages plant-based collagen to provide a natural solution for maintaining youthful and radiant skin. Vegan collagen, the key ingredient and a...
PR Newswire
23/05/2024

Bionoxx to Highlight Innovative Strategy for Addressing Immune-Related Diseases…

Bionoxx research has discovered that cancer patients exhibit impaired neutrophil homeostatic dynamics in their peripheral blood, a condition that may significantly contribute to T cell dysfunction and suboptimal clinical outcomes in these individuals. BNX has pioneered the BNX-IFS, a novel technology aimed at identifying activated neutrophils linked to T cell homeostasis within circulating immune cells. Bionoxx has already received clearance of an Investigational New Drug (IND) application by…
PR Newswire
23/05/2024

Invizius's Pioneering Dialysis Product H-Guard® Completes First In-Human…

The study investigated the safety of H-Guard® in patients undergoing haemodialysis who are vulnerable to dialysis-induced immune activation. H-Guard® is flushed through the dialysis machine, coating all blood exposed surfaces prior to treatment. The study investigated the safety of H-Guard® in patients undergoing haemodialysis who are vulnerable to dialysis-induced immune activation. H-Guard® is flushed through the dialysis machine, coating all blood exposed surfaces prior to treatment...
PR Newswire
23/05/2024

DELSITECH ANNOUNCES A MAJOR LICENSING AGREEMENT ON DRUG DELIVERY

"We are excited to announce the second license agreement in the first half of 2024 with a global pharmaceutical partner," said Lasse Leino, Chief Executive Officer at DelSiTech. "These successes continue to validate our sustained hard work for the benefit of patients in need of vital new therapies." "We are excited to announce the second license agreement in the first half of 2024 with a global pharmaceutical partner," said Lasse Leino, Chief Executive Officer at…
PR Newswire
23/05/2024

Information on the Total Number of Voting Rights (Denominator) following…

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion...
Nasdaq GlobeNewswire
23/05/2024

Calliditas Q1 report, January - March 2024

JANUARY - MARCH 2024 (COMPARED TO JANUARY - MARCH 2023) JANUARY -MARCH 2024(COMPARED TO JANUARY -MARCH 2023 ) "In Q1 we generated another record quarter in terms of demand with 705 enrollments and 354 new prescribers. We are very excited over this positive trend, and we continue to see strong demand in Q2 ." - CEO Renée Aguiar-Lucander. KEY TAKEAWAYS FROM Q1, 2024 KEY EVENTS AFTER THE REPORTING PERIOD KEY...
PR Newswire
23/05/2024

ONWARD® Medical Reports Q1 2024 Update and Year-to-Date Highlights

Nature Medicine published Up-LIFT pivotal trial results Submitted FDA De Novo application for ARC-EX ®SystemSuccessfully raised EUR 20M in equity capital EINDHOVEN, the Netherlands, May23, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today provided a Q1 2024 business update.“This...
Nasdaq GlobeNewswire
23/05/2024

Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders

Allschwil, Switzerland – May 23, 2024Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Annual Report of the year ending December 31, 2023, will be held on Thursday, June 13, 2024, at 09.00 CEST at the Congress Center, Messe Basel, Switzerland. Notes to ShareholdersThe invitation was published in the Swiss Official Gazette of Commerce (Schweizerisches...
Nasdaq GlobeNewswire
23/05/2024

EUROAPI strengthens its presence in animal health with a €130-150 million supply…

Press Release A 5-year manufacturing contract to support the FOCUS-27 project sales trajectoryThis contract highlights EUROAPI's know-how and the reliability of its premium Contract Manufacturing Organization services to customersParis – May 23, 2024– EUROAPI announces today that it has entered into a Contract Manufacturing Organization (CMO) agreement with a global animal health company. As part of this collaboration, EUROAPI will supply its client with a key...
Nasdaq GlobeNewswire
23/05/2024

Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data…

Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease Additional kidney function analyses strongly support Vivoryon's shift in strategic focus to inflammatory and fibrotic diseases, and are a further step towards securing Company's futureVaroglutamstat`s beneficial effect of improving kidney function, as demonstrated by an increase of estimated glomerular filtration rate (eGFR), confirmed by various sensitivity...
Nasdaq GlobeNewswire
23/05/2024

IBA Business Update – First Quarter 2024

Louvain-la-Neuve, Belgium, 23 May 2024- IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the first quarter ending 31 March 2024.Group OverviewGood Group order intake at end of March, driven by continued growth in Other Accelerators, with typical strong second half weighting expectedGroup backlog remains at a high of EUR 1.4 billionEUR 30.1 million net cash position, decreasing as a result of a planned...
Nasdaq GlobeNewswire
23/05/2024

Bulletin from the Annual General Meeting of Implantica AG

The general meeting resolved to carry forward the net loss for the financial year 2023 in accordance with the adopted balance sheet and to no payment of dividend. The general meeting resolved to carry forward the net loss for the financial year 2023 in accordance with the adopted balance sheet and to no payment of dividend. The general meeting resolved to discharge the members of the board of directors, the executive management and the auditors from liability for their services in the...
PR Newswire
23/05/2024

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Register Stunning…

Key Takeaways from the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Report Key Takeaways from the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Report Discover which therapies are expected to grab the major CAR T-Cell therapy for ALL market share @CAR T-Cell therapy for ALL Market Report CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Overview Acute lymphocytic leukemia (ALL), alternatively known as acute lymphoblastic leukemia, is a form of...
PR Newswire
22/05/2024

Nyxoah Announces Reduction of the Maximum Amount Available Under its At…

REGULATED INFORMATION INSIDE INFORMATIONNyxoah Announces Reduction of the Maximum Amount Available Under its At-the-Market Equity Offering Program Mont-Saint-Guibert, Belgium – May 22, 2024, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today that it has reduced the maximum amount...
Nasdaq GlobeNewswire
22/05/2024

Nyxoah Announces Proposed Offering of Ordinary Shares

REGULATED INFORMATION INSIDE INFORMATIONNyxoah Announces Proposed Offering of Ordinary SharesMont-Saint-Guibert, Belgium – May 22, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today the commencement of a proposed underwritten public offering in the United States, which may...
Nasdaq GlobeNewswire
22/05/2024

Inventiva announces two scientific presentations at the EASL International Liver…

The first abstract demonstrates that the improvements of MACK-3, a diagnostic test for metabolic dysfunction-associated steatohepatitis, parallel the histological response to lanifibranor therapy in patients with MASH/NASH, in the NATIVE Phase IIb clinical trial.The second abstract brings additional evidence supporting the role of intrahepatic vascular alterations in the development of MASLD-related portal hypertension and the progression to MASH and highlights the potential of lanifibranor...
Nasdaq GlobeNewswire
22/05/2024

The US Sleep Supplements Market is Set to Reach $1.45 Billion by 2029 -…

The US Sleep Supplements Market Report Scope The US Sleep Supplements Market Report Scope The US sleep supplements market is growing significantly due to a surge in online sales and increasing demand for plant-based options. Lifestyle factors such as stress, irregular sleep patterns, and changing demographics, notably an aging population and health-conscious millennials, are driving this trend. The convenience of online purchasing has made sleep supplements more accessible, while the...
PR Newswire
22/05/2024

The US Neonatal Incubators Market to Reach $121.11 Million by 2029 - Specialty…

The U.S. Neonatal Incubators Market Report Scope The U.S. Neonatal Incubators Market Report Scope The infant incubator market is highly fragmented, with many producers in the US. To meet the surging consumer demand and expand their customer base, these companies are implementing various tactics such as mergers & acquisitions, partnerships & collaborations, and new product launches. Owing to the presence of well-established NICUs and neonatal care, the US market is likely to witness...
PR Newswire
22/05/2024
Altri  Comunicati